Small-Molecule Screening Identifies the Selanazal Drug Ebselen as a Potent Inhibitor of DMT1-Mediated Iron Uptake
- 22 September 2006
- journal article
- Published by Elsevier BV in Cell Chemical Biology
- Vol. 13 (9), 965-972
- https://doi.org/10.1016/j.chembiol.2006.08.005
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Cannabinoid signallingLife Sciences, 2005
- Inhibition of NF-κB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Identification of Small Molecule Inhibitors that Distinguish between Non-Transferrin Bound Iron Uptake and Transferrin-Mediated Iron TransportCell Chemical Biology, 2004
- A Spontaneous, Recurrent Mutation in Divalent Metal Transporter-1 Exposes a Calcium Entry PathwayPLoS Biology, 2004
- Reduction of Fe(III) Ions Complexed to Physiological Ligands by Lipoyl Dehydrogenase and Other Flavoenzymes in VitroPublished by Elsevier BV ,2003
- A Novel Antioxidant Mechanism of Ebselen Involving Ebselen Diselenide, a Substrate of Mammalian Thioredoxin and Thioredoxin ReductasePublished by Elsevier BV ,2002
- The Chelatable Iron Pool in Living Cells: A Methodically Defined QuantityBiological Chemistry, 2002
- Ebselen in Acute Ischemic StrokeStroke, 1998
- Molecular actions of Ebselen—an antiinflammatory antioxidantGeneral Pharmacology: The Vascular System, 1995
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976